Grant: Doctoral: Vanier Canada Graduate Scholarships
McGill University
$150,000.00
Characterization of Alpha-Synuclein Aggregation Using Parkinson Disease Patient-Derived Midbrain Organoids
FY 2022-23
Summary
Supervisor: Edward Fon, McGill University
Parkinson's Disease (PD) is the second leading cause of neurodegenerative disease affecting the brain with over 100,000 Canadians currently living with the disease. Patients suffer from symptoms in mental ability and mobility such as depression and slowness of movement, respectively. Alpha-synuclein (Syn) is a protein in the brain which clusters together in PD in a process called aggregation. Aggregation of Syn is thought to cause much of the damage observed in PD patients' brains. However, in different PD patients, Syn can behave very differently.
Effective therapies to hinder PD or reverse the damage have been sorely lacking, and this may be explained, in part, because many models used to study PD and develop therapeutics have not yet addressed specific differences in Syn aggregates that form in different patients. Therefore, there is a need for better models and a personalized approach to studying PD.
This project proposes the use of 3D organoids: a miniature brain-like structure composed of cells collected directly from PD patients. Using organoids carrying mutations in the SNCA gene (responsible for producing Syn) permits us to understand how a specific patient's genetics affect the aggregation behavior of Syn. Using biochemical techniques, aggregation of Syn will be analyzed to compare between what occurs when Syn is in abundance, depleted, or under normal conditions. Furthermore, different Syn aggregates will be visualized via advanced microscopy techniques to analyze them structurally.
PD is different from patient to patient, and much of this difference could be due to the differences in Syn aggregation. Using organoids from PD patients with SNCA mutations, we can begin to tailor our approach to understanding PD. This is the first project of its kind to attempt such a feat, and if successful, it can be an important stepping-stone towards developing effective and personalized treatments to PD.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
474479
Name
Al-Azzawi Zaid
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Characterization of Alpha-Synuclein Aggregation Using Parkinson Disease Patient-Derived Midbrain Organoids
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Alpha Synuclein Aggregation; Alphy Synuclein Aggregate Strains; Cryogenic Electron Microscopy; Human Midbrain Organoids; Parksinson Disease Pathology; Protein Misfolding Cyclic Amplification; Real-Time Quaking-Induced Conversion
Abstract
Supervisor: Edward Fon, McGill University
Parkinson's Disease (PD) is the second leading cause of neurodegenerative disease affecting the brain with over 100,000 Canadians currently living with the disease. Patients suffer from symptoms in mental ability and mobility such as depression and slowness of movement, respectively. Alpha-synuclein (Syn) is a protein in the brain which clusters together in PD in a process called aggregation. Aggregation of Syn is thought to cause much of the damage observed in PD patients' brains. However, in different PD patients, Syn can behave very differently.
Effective therapies to hinder PD or reverse the damage have been sorely lacking, and this may be explained, in part, because many models used to study PD and develop therapeutics have not yet addressed specific differences in Syn aggregates that form in different patients. Therefore, there is a need for better models and a personalized approach to studying PD.
This project proposes the use of 3D organoids: a miniature brain-like structure composed of cells collected directly from PD patients. Using organoids carrying mutations in the SNCA gene (responsible for producing Syn) permits us to understand how a specific patient's genetics affect the aggregation behavior of Syn. Using biochemical techniques, aggregation of Syn will be analyzed to compare between what occurs when Syn is in abundance, depleted, or under normal conditions. Furthermore, different Syn aggregates will be visualized via advanced microscopy techniques to analyze them structurally.
PD is different from patient to patient, and much of this difference could be due to the differences in Syn aggregation. Using organoids from PD patients with SNCA mutations, we can begin to tailor our approach to understanding PD. This is the first project of its kind to attempt such a feat, and if successful, it can be an important stepping-stone towards developing effective and personalized treatments to PD.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Al-Azzawi, Zaid
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~